Pharm-Olam International Ltd. (POI) has signed three contracts with a total value of $13.4 million. The contracts involve patient recruitment, site selection, project management, biostatistics, monitoring, and regulatory affairs in the therapeutic areas of pain, cardiovascular disease, and ophthalmology. The trials involve more than 1,000 patients, from sites across Central and Eastern Europe. “Selecting sites outside the U.S. was the logical choice because the large numbers of treatm...